Abstract
Background
It has been suggested that specific antihypertensive medications (AHT) may either increase or decrease breast cancer risk.
Methods
We studied breast cancer incidence among 49,950 women in North Jutland, Denmark in order to determine if breast cancer risk is associated with specific classes of AHT use. Poisson regression analyses were used to calculate rate ratios for ever or exclusive use of each class of AHT, number of prescriptions for AHT, and years of follow-up.
Results
There was no statistically significant association between ever use of any AHT overall (RR = 0.95; 95% CI = 0.81–1.10) or any specific class of AHT (diuretics, beta blockers, calcium channel blockers (CCBs), angiotensin converting enzyme (ACE) inhibitors, and angiotensin II antagonists) and breast cancer.
Conclusions
This study should offer further reassurance to women currently using AHT that their medication use is unlikely related to breast cancer risk.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kizer JR, Kimmel SE Epidemiologic review of the calcium channel blocker drugs An up-to-date perspective on the proposed hazards Arch Intern Med 2001 161(9): 1145–1158
Felmeden DC, Lip GYH Antihypertensive therapy and cancer risk Drug Safety 2001 24(10): 727–739
Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL Use of calcium channel blockers and breast carcinoma risk in postmenopausal women Cancer 1997 80(8): 1438–1447
Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, Andersen M, Fraumeni JF Jr, Olsen J Cancer risk in users of calcium channel blockers Hypertension 1997 29(5): 1091–1094
Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, Baron JA Cancer risk and mortality in users of calcium channel blockers A cohort study Cancer 2000 89(1): 165–170
Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR Calcium-channel blockers and risk of cancer Lancet 1997 349: 525–528
Meier CR, Derby LE, Jick SS, Jick H Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer Arch Intern Med 2000 160: 349–353
Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998 351: 1292–1296
Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore Cancer Res 2003 63(3): 573–578
Yuan JM, Koh WP, Sun CL, Lee HP, Yu MC: Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. 2005 Mar 31; [Epub ahead of print]
Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark Cancer 2001 92(9): 2462–2470
Stahl M, Bulpitt CJ, Palmer AJ, Beevers DG, Coles EC, Webster J Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP) J Hum Hypertens 2000 14(5): 285–286
Grossman E, Messerli FH, Goldbourt U Antihypertensive therapy and the risk of malignancies Eur Heart J 2001 22(15): 1343–1352
Capella D, 1993 Descriptive tools and analysis. In: Dukes MNG, (ed). Drug Utilization Studies: Methods and Uses. WHO regional publications (European series no. 45). World Health Organization, Geneva, 55–78
The WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Oslo, Norway: Norwegian Institute of Public Health; [updated 2004 Jan 5; cited 2004 Jul 27]. Available from: http://www.whocc.no/atcddd/
Storm HH, Michelsen EV, Clemmensen IH, Pihl J The Danish Cancer Registry-history, content, quality, and use Dan Med Bull 1997 44: 535–539
Gaist D, Sorensen HT, Hallas J. The Danish prescription registries Dan Med Bull 1997 44: 445–448
Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years Cancer 2003 98(7): 1504–5113
Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA Breast cancer incidence and use of antihypertensive medication in women Pharmacoepidemiol Drug Saf 2004 13(8): 581–585
Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shapiro S Calcium channel blockers and the risk of cancer JAMA 1998 279(13): 1000–1004
Jonas M, Goldbourt U, Boyko V, Mandelzweig L, Behar S, Reicher-Reiss H Nifedipine and cancer mortality: 10-year follow-up of 2607 patients after acute myocardial infarction Cardiovasc Drugs Ther 1998 12(2): 177–181
Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ Calcium-channel blockade and incidence of cancer in aged populations Lancet 1996 348(9026): 493–497
Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JW, Gillis CR, et al. Incidence of and mortality from␣cancer in hypertensive patients BMJ 1993 306: 609–611
Acknowledgement
This study was funded by the International Epidemiology Institute, Rockville, Maryland, USA, the Ingeborg and Leo Dannins Foundation for Scientific Research, and the Western Danish Research Forum for Health Sciences (Vestdansk Forskningsforum).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fryzek, J.P., Poulsen, A.H., Lipworth, L. et al. A Cohort Study of Antihypertensive Medication Use and Breast Cancer Among Danish Women. Breast Cancer Res Treat 97, 231–236 (2006). https://doi.org/10.1007/s10549-005-9091-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-9091-x